Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr 3;15(1):53.
doi: 10.1038/s41408-025-01259-z.

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Carlyn Rose Tan  1 , Sireesha Asoori  2 , Chiung-Yu Huang  2 , Larissa Brunaldi  3 , Rakesh Popat  4 , Efstathios Kastritis  5 , Joaquin Martinez-Lopez  6 , Radhika Bansal  3 , Andre De Menezes Silva Corraes  3 , Saurabh Chhabra  7 , Ricardo Parrondo  8 , Sikander Ailawadhi  8 , Despina Fotiou  5 , Meletios A Dimopoulos  5 , Kwee Yong  4 , Catriona Mactier  4 , Chris Lau  4 , Magdalena Corona  6 , Adolfo Jesús Sáez Marin  6 , Hira Mian  9 , Brian Gm Durie  10 , Saad Z Usmani  11 , Thomas G Martin  12 , Yi Lin  3
Affiliations
Multicenter Study

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Carlyn Rose Tan et al. Blood Cancer J. .

Abstract

Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46-61%) and 73% (67-80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33-55%] vs 63% [54-73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CRT reports research funding from Janssen and Takeda, personal fees from MJH Life Sciences, and has received honoraria for consultancy/participated in the advisory boards for Janssen and Sanofi. RK reports research funding from Pfizer and GSK, consultancy for Roche and GSK, and has received honoraria from J&J, AbbVie, BMS, Pfizer, and GSK. EK has received honoraria from Janssen/J&J, GSK, Sanofi, and Pfizer and reports institutional research funding from Janssen/J&J, GSK, and Pfizer. JM-L reports research funding from Janssen, Pfizer, Incity, consultancy for Amgen, Janssen, BMS, Pfizer, Kite, Roche, and has received honoraria from Amgen, Janssen, BMS, Pfizer, Kite, Roche. RB reports travel support from Kite Pharma. SB reports honoraria from Sanofi, Sobi, Ascentage Pharma and institutional research funding from AbbVie, C4 therapeutics, Carsgen, Takeda, and Johnson & Johnson. RP reports research funding from GSK and Bristol-Myers Squibb foundation, and consultancy for Astra Zeneca and Sanofi Aventis. SA reports institutional research funding from GSK, BMS, Pharmacyclics, Amgen, Sanofi, Janssen, Cellectar, Xencor, AbbVie, and Ascentage, and consultancy for GSK, Sanofi, BMS, Takeda, Beigene, Regeneron, Pharmacyclics, Amgen, and Janssen. DF has received honoraria from Janssen and Sanofi. MAD has received honoraria from Amgen, Takeda, Janssen-Cilag, Bristol-Myers Squibb, Beigene, and Sanofi, and reports consulting or advisory roles for Amgen, Janssen-Cilag, Takeda, Bristol-Myers Squibb, Beigene, Sanofi. HM reports research funding from Janssen and Pfizer and has received honoraria/participated in advisory boards for Janssen/J&J, GSK, Sanofi, Pfizer, Takeda, and AbbVie. SZU received research funding from Amgen, AbbVie, Array Biopharma, BMS, Celgene, Gilead, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda, and is a consultant to AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Gracell, Janssen, Oncopeptides, Pfizer, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio. TGM reports research funding from Sanofi, Janssen, Amgen, and BMS and is a consultant for GSK, Roche, and Pfizer. YL reports institutional research funding from Janssen and BMS, has participated in advisory boards for Janssen, Sanofi, BMS, Regeneron, Genentech, Tessera, and Legend, has participated in Steering Committees for Janssen and Kite/Gilead, and has participated in scientific advisory boards for NexImmune, Caribou, and has participated in a Data Safety Monitoring Board for Pfizer. Consent to participate: Individual informed consent was obtained per each participating center’s institutional requirements and guidelines. Ethical approval: This study received approval from the Institutional Review Boards of the respective participating institutions, including Memorial Sloan Kettering Cancer Center IRB (#24-044). The research was performed in compliance with the terms of the Declaration of Helsinki, and all methods were performed in accordance with the relevant guidelines and regulations.

Figures

Fig. 1
Fig. 1. Responses to teclistamab in patients with relapsed/refractory multiple myeloma.
A Stacked bar graph illustrating the rate of PR, VGPR, CR, and sCR in 188 response-evaluable patients treated with teclistamab. Responses according to IMWG criteria. B Forest Plot of ORR in Subgroups.
Fig. 2
Fig. 2. Progression-free survival, overall survival, and duration of response of real-world patients treated with teclistamab.
A Progression-free survival (PFS). B Overall survival (OS). C Duration of response (DoR).
Fig. 3
Fig. 3. PFS of real-world teclistamab in subgroups.
A PFS according to prior BCMA exposure. B PFS according to the type of prior BCMA-directed agent. C PFS according to cytogenetic risk. D PFS according to creatinine clearance. E PFS according to penta-drug refractoriness. F PFS according to MajesTEC-1 eligibility.
Fig. 4
Fig. 4. OS of real-world teclistamab in subgroups.
A OS according to prior BCMA exposure. B OS according to the type of prior BCMA-directed agent. C OS according to cytogenetic risk. D OS according to creatinine clearance. E OS according to penta-drug refractoriness. F OS according to MajesTEC-1 eligibility.
See this image and copyright information in PMC

References

    1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. - DOI - PMC - PubMed
    1. Garfall, Nooka AL, Donk AK, NWCJvd, Moreau P, Bhutani M, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:7540. - DOI
    1. Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886–900. - PubMed
    1. Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:8–17.e6. - DOI - PubMed
    1. Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17:575–83.e2. - DOI - PubMed

Publication types

Substances